AAA
MBX

Affinity Asset Advisors’s MBX Biosciences MBX Stock Holding History

Affinity Asset Advisors’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.48M Sell
150,000
-100,000
-40% -$3.4M 0.23% 73
2025
Q4 		$7.88M Buy
250,000
+85,000
+52% +$2.06M 0.45% 51
2025
Q3 		$2.89M Buy
+165,000
New +$2.21M 0.25% 65
2025
Q2 		– Sell
-175,000
Closed -$1.29M – 118
2025
Q1 		$1.29M Buy
+175,000
New +$1.85M 0.12% 76

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Affinity Asset Advisors's MBX Position: Q1 2026 in Review

Affinity Asset Advisors reduced its MBX Biosciences (MBX) stake by 40% in Q1 2026, selling an estimated $3.4M and leaving 150,000 shares worth $4.48M. The position accounts for 0.23% of the portfolio, ranked #73.

Affinity Asset Advisors first reported a position in MBX in Q1 2025 and has held it in 4 quarters since. The position peaked at $7.88M in Q4 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Affinity Asset Advisors held 150,000 shares of MBX Biosciences worth $4.48M as of Q1 2026.
  • Affinity Asset Advisors sold 100,000 MBX Biosciences shares in Q1 2026, an estimated $3.4M.
  • MBX Biosciences made up 0.23% of Affinity Asset Advisors's portfolio in Q1 2026, its #73 holding.
  • Affinity Asset Advisors first reported a position in MBX Biosciences in Q1 2025 and has held it in 4 quarters since.
  • Affinity Asset Advisors's MBX Biosciences position peaked at $7.88M in Q4 2025.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.